Multiple Plasmodium proteins

Multiple Plasmodium proteins refers to the collective set of molecular targets within the Plasmodium parasite species, such as P. falciparum and P. vivax, which are responsible for causing malaria. This designation is frequently employed in pharmacology to describe the action of broad-spectrum antimalarial agents like artemisinins, which do not bind to a single receptor but instead undergo activation to form free radicals that covalently modify and inactivate a wide array of essential parasite proteins involved in glycolysis, protein folding, and redox balance (Wang et al., 2015; Nature Communications). The term also encompasses the targets of multi-stage or whole-organism vaccines designed to elicit a robust immune response against various antigens presented during the sporozoite, merozoite, and gametocyte stages of the parasite's complex life cycle (Duffy et al., 2012; NPJ Vaccines). By affecting multiple pathways simultaneously, these therapeutic strategies aim to maximize parasiticidal efficacy and increase the genetic barrier to the development of drug resistance. However, the non-specific nature of this target profile can complicate the identification of precise molecular mechanisms and the monitoring of emerging resistance patterns in clinical settings (Tilley et al., 2016; Trends in Parasitology).

Other names

Plasmodium proteomePlasmodium antigensMulti-target antimalarial targetsPlasmodium falciparum proteins

Drugs targeting multiple Plasmodium proteins typically act through the covalent alkylation of various essential parasite proteins (as seen with artemisinins), the inhibition of multiple enzymes in the folate synthesis pathway, or the disruption of heme detoxification mechanisms across different life-cycle stages (Wang et al., 2015; Tilley et al., 2016).